Drs. Altschuler, Wu, and Lomen-Hoerth are developing a digital health platform that leverages artificial intelligence to analyze diverse patient data for amyotrophic lateral sclerosis (ALS). The platform seeks to capture high-resolution measures of disease progression, identify distinct patterns in patient subgroups, and link early-stage digital and molecular markers to patient outcomes, an approach that could transform clinical trials, treatment personalization, and patient care in ALS and potentially other complex diseases lacking clear genetic signatures.
